Blueprint Medicines (BPMC) Reports Q3 Loss, Tops Revenue Estimates

Blueprint Medicines (BPMC) came out with a quarterly loss of $0.89 per share versus the Zacks Consensus Estimate of a loss of $0.97. This compares to loss of $2.20 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 8.25%. A quarter ago, it was expected that this cancer drug developer would post a loss of $1.28 per share when it actually produced a loss of $0.80, delivering a surprise of 37.50%. Over the last four quarters, the c ...